Research Reports, page-487

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping 

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

ASX Market Close: Index creeps lower as half-year mark approaches | June 26

'Not possible' to port renewable gas: ACCC takes AGN to court

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates